News >

Lenalidomide/Rituximab Combo Nears EU Approval for Follicular Lymphoma

Gina Columbus @ginacolumbusonc
Published: Friday, Nov 15, 2019

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci., president of the European Hematology Association and Centre for Haemato-Oncology, Barts Cancer Institute

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the combination of lenalidomide (Revlimid) and rituximab (Rituxan; R2) for the treatment of adult patients with grade 1 to 3a previously treated follicular lymphoma.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication